<!DOCTYPE html>
<html lang="en">
<head>
  <meta name="google-site-verification" content="Ro7wjQYEf4inq7N5mwGi9fZbQObUY3tOQfM-8jQzgz8" />
  <meta charset="UTF-8" />
  <title>Elisence UK – Sovereign Digital Health & AI</title>
  <meta name="description" content="Elisence UK – the sovereign digital health & AI platform led by founder Saami (Sami) Salami Asl, building safe, non-diagnostic health intelligence for the United Kingdom and beyond.">
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <!-- Canonical: main identity stays on elisence.com -->
  <link rel="canonical" href="https://www.elisence.com/" />

  <!-- Open Graph -->
  <meta property="og:title" content="Elisence UK – Sovereign Digital Health & AI">
  <meta property="og:description" content="Official UK presence of Elisence and founder Saami (Sami) Salami Asl – digital health, safety and humanity.">
  <meta property="og:type" content="website">
  <meta property="og:url" content="https://www.elisence.co.uk/">
  <meta property="og:site_name" content="Elisence UK">

  <!-- Organization JSON-LD -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "name": "Elisence",
    "url": "https://www.elisence.com",
    "logo": "https://www.elisence.com/assets/logo.png",
    "founder": {
      "@type": "Person",
      "name": "Saami Salami Asl"
    }
  }
  </script>

  <style>
    :root {
      --bg-deep: #020617;
      --bg-card: rgba(15, 23, 42, 0.96);
      --border-soft: rgba(148, 163, 184, 0.45);
      --accent: #38bdf8;
      --accent-soft: rgba(56, 189, 248, 0.3);
      --accent-strong: rgba(59, 130, 246, 0.7);
      --text-main: #e5e7eb;
      --text-soft: #cbd5f5;
      --text-muted: #9ca3af;
    }

    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      background:
        radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
        radial-gradient(circle at bottom right, rgba(59, 130, 246, 0.16), transparent 55%),
        var(--bg-deep);
      color: var(--text-main);
      line-height: 1.7;
    }

    .shell {
      min-height: 100vh;
      display: flex;
      flex-direction: column;
    }

    header {
      padding: 26px 18px 8px;
      border-bottom: 1px solid rgba(15, 23, 42, 0.9);
      background: linear-gradient(to bottom, rgba(15, 23, 42, 0.96), transparent);
      backdrop-filter: blur(12px);
    }

    .header-inner {
      max-width: 1120px;
      margin: 0 auto;
      display: flex;
      align-items: center;
      justify-content: space-between;
      gap: 16px;
    }

    .brand {
      display: flex;
      align-items: center;
      gap: 10px;
    }

    .brand-mark {
      width: 34px;
      height: 34px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.6);
      background: radial-gradient(circle at 30% 10%, rgba(56, 189, 248, 0.7), transparent 55%),
                  radial-gradient(circle at 70% 80%, rgba(59, 130, 246, 0.75), transparent 60%),
                  #020617;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 0.9),
        0 0 18px rgba(56, 189, 248, 0.65);
    }

    .brand-text-main {
      font-weight: 600;
      letter-spacing: 0.08em;
      font-size: 0.9rem;
      text-transform: uppercase;
    }

    .brand-text-sub {
      font-size: 0.8rem;
      color: var(--text-soft);
    }

    .top-links {
      display: flex;
      gap: 10px;
      flex-wrap: wrap;
      justify-content: flex-end;
    }

    .chip {
      font-size: 0.75rem;
      padding: 4px 10px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.7);
      background: radial-gradient(circle at top, rgba(56, 189, 248, 0.28), rgba(15, 23, 42, 0.98) 55%);
      color: var(--text-soft);
      text-decoration: none;
      display: inline-flex;
      align-items: center;
      gap: 6px;
      box-shadow:
        0 0 12px rgba(56, 189, 248, 0.5),
        0 10px 30px rgba(15, 23, 42, 0.95);
    }

    .chip span {
      font-size: 0.8rem;
    }

    main {
      flex: 1;
      max-width: 1120px;
      margin: 0 auto;
      padding: 26px 18px 40px;
    }

    .hero {
      display: grid;
      grid-template-columns: minmax(0, 3fr);
      gap: 18px;
      margin-bottom: 22px;
    }

    .pill {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 3px 10px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.6);
      background: rgba(15, 23, 42, 0.92);
      color: var(--text-soft);
      font-size: 0.75rem;
      text-transform: uppercase;
      letter-spacing: 0.1em;
      margin-bottom: 10px;
      box-shadow: 0 0 18px rgba(56, 189, 248, 0.45);
    }

    .pill-dot {
      width: 7px;
      height: 7px;
      border-radius: 999px;
      background: var(--accent);
      box-shadow: 0 0 12px rgba(56, 189, 248, 0.9);
    }

    h1 {
      margin: 0;
      font-size: 1.9rem;
      letter-spacing: 0.03em;
    }

    .hero-sub {
      margin-top: 8px;
      color: var(--text-soft);
      font-size: 0.95rem;
    }

    .hero-sub strong {
      color: #f9fafb;
    }

    .hero-actions {
      margin-top: 18px;
      display: flex;
      flex-wrap: wrap;
      gap: 10px;
    }

    .btn {
      border-radius: 999px;
      padding: 8px 18px;
      font-size: 0.9rem;
      border: 1px solid var(--accent-strong);
      background: radial-gradient(circle at top, rgba(59, 130, 246, 0.9), rgba(37, 99, 235, 0.95));
      color: #f9fafb;
      text-decoration: none;
      display: inline-flex;
      align-items: center;
      gap: 8px;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 1),
        0 12px 32px rgba(37, 99, 235, 0.85),
        0 0 22px rgba(59, 130, 246, 0.8);
      transform: translateY(0);
      transition: transform 0.16s ease, box-shadow 0.16s ease, background 0.16s ease;
    }

    .btn:hover {
      transform: translateY(-1px);
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 1),
        0 16px 40px rgba(37, 99, 235, 0.95),
        0 0 26px rgba(59, 130, 246, 0.95);
    }

    .btn-outline {
      background: radial-gradient(circle at top, rgba(15, 23, 42, 0.98), rgba(15, 23, 42, 1));
      border-color: rgba(148, 163, 184, 0.9);
      color: var(--text-soft);
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 1),
        0 10px 30px rgba(15, 23, 42, 0.95),
        0 0 18px rgba(56, 189, 248, 0.5);
    }

    .btn-outline:hover {
      border-color: var(--accent-strong);
      color: #e5e7eb;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 1),
        0 14px 36px rgba(15, 23, 42, 0.98),
        0 0 22px rgba(56, 189, 248, 0.7);
    }

    .section-grid {
      display: grid;
      grid-template-columns: minmax(0, 3fr) minmax(0, 2.4fr);
      gap: 18px;
      margin-top: 24px;
      flex-wrap: wrap;
    }

    .panel {
      border-radius: 16px;
      border: 1px solid var(--border-soft);
      background:
        radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
        radial-gradient(circle at bottom right, rgba(30, 64, 175, 0.45), transparent 60%),
        var(--bg-card);
      padding: 18px 18px 16px;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 0.96),
        0 24px 60px rgba(15, 23, 42, 1),
        0 0 28px rgba(37, 99, 235, 0.55);
    }

    .panel h2 {
      margin: 0 0 8px;
      font-size: 1.1rem;
    }

    .panel p {
      margin: 6px 0;
      font-size: 0.94rem;
      color: var(--text-main);
    }

    .panel small {
      color: var(--text-muted);
      font-size: 0.8rem;
    }

    .link-list {
      margin: 8px 0 0;
      padding-left: 18px;
      font-size: 0.9rem;
    }

    .link-list li {
      margin: 4px 0;
      color: var(--text-soft);
    }

    .link-list a {
      color: var(--accent);
      text-decoration: none;
    }

    .link-list a:hover {
      text-decoration: underline;
    }

    /* Articles grid with 11 cards */
    .articles-section {
      margin-top: 28px;
    }

    .articles-title {
      font-size: 1.1rem;
      margin-bottom: 10px;
    }

    .articles-sub {
      font-size: 0.9rem;
      color: var(--text-soft);
      margin-bottom: 16px;
    }

    .articles-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(240px, 1fr));
      gap: 16px;
    }

    .article-card {
      border-radius: 14px;
      border: 1px solid var(--border-soft);
      background:
        radial-gradient(circle at top left, rgba(56, 189, 248, 0.16), transparent 55%),
        radial-gradient(circle at bottom right, rgba(30, 64, 175, 0.4), transparent 60%),
        var(--bg-card);
      padding: 14px 14px 13px;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 0.96),
        0 18px 40px rgba(15, 23, 42, 1),
        0 0 20px rgba(37, 99, 235, 0.5);
    }

    .article-eyebrow {
      font-size: 0.72rem;
      text-transform: uppercase;
      letter-spacing: 0.12em;
      color: var(--text-muted);
      margin-bottom: 4px;
    }

    .article-title {
      font-size: 0.98rem;
      font-weight: 600;
      margin: 0 0 6px;
    }

    .article-text {
      font-size: 0.88rem;
      color: var(--text-soft);
      margin: 0 0 8px;
    }

    .article-link {
      font-size: 0.85rem;
      color: var(--accent);
      text-decoration: none;
    }

    .article-link:hover {
      text-decoration: underline;
    }

    footer {
      border-top: 1px solid rgba(15, 23, 42, 0.9);
      padding: 16px 18px 22px;
      font-size: 0.8rem;
      color: var(--text-muted);
      background: radial-gradient(circle at top, rgba(15, 23, 42, 0.98), rgba(15, 23, 42, 1));
    }

    .footer-inner {
      max-width: 1120px;
      margin: 0 auto;
      display: flex;
      flex-wrap: wrap;
      justify-content: space-between;
      gap: 10px;
      align-items: center;
    }

    .footer-inner a {
      color: var(--accent);
      text-decoration: none;
      font-size: 0.8rem;
    }

    .footer-inner a:hover {
      text-decoration: underline;
    }

    @media (max-width: 800px) {
      .header-inner {
        flex-direction: column;
        align-items: flex-start;
      }
      .top-links {
        justify-content: flex-start;
      }
      .section-grid {
        grid-template-columns: minmax(0, 1fr);
      }
      .hero-actions {
        flex-direction: column;
        align-items: flex-start;
      }
    }
  </style>
</head>
<body>
  <div class="shell">
    <header>
      <div class="header-inner">
        <div class="brand">
          <div class="brand-mark"></div>
          <div>
            <div class="brand-text-main">ELISENCE</div>
            <div class="brand-text-sub">Global Digital Health & Humanity Platform</div>
          </div>
        </div>
        <div class="top-links">
          <a class="chip" href="https://www.elisence.com/" rel="noopener">
            <span>Go to main platform</span>
          </a>
          <a class="chip" href="https://www.elisence.com/qatar.html" rel="noopener">
            <span>Government & Ministry briefings</span>
          </a>
        </div>
      </div>
    </header>

    <main>
      <section class="hero">
        <div>
          <div class="pill">
            <span class="pill-dot"></span>
            <span>United Kingdom • Official Microsite</span>
          </div>
          <h1>Elisence UK – Sovereign Digital Health & AI</h1>
          <p class="hero-sub">
            Elisence is a global digital health ecosystem led by founder
            <strong>Saami Salami Asl</strong>
            (also written as <strong>Sami Salami Asl, Saami Salami or Sami Salami</strong>),
            building safe, non-diagnostic health intelligence for families, clinicians and ministries.
          </p>
          <div class="hero-actions">
            <a class="btn" href="https://www.elisence.com/founder-saami.html" rel="noopener">
              Meet the founder
            </a>
            <a class="btn btn-outline" href="https://www.elisence.com/phases.html" rel="noopener">
              Explore all 17 Elisence phases
            </a>
          </div>
        </div>
      </section>

      <section class="section-grid">
        <div class="panel">
          <h2>Why a UK-focused Elisence microsite?</h2>
          <p>
            Search engines sometimes surface an incomplete or distorted picture of a person. This UK microsite exists
            to make it clear that <strong>Saami / Sami Salami Asl</strong> is the founder of a serious, long-term
            digital health platform – not a social media project – and that Elisence is designed to work alongside
            NHS-style systems and regulators.
          </p>
          <p>
            For any due-diligence, legal, clinical or investment review, please use the official Elisence materials and
            evidence packs on the global website as the primary reference.
          </p>
          <ul class="link-list">
            <li>
              Founder master page:
              <a href="https://www.elisence.com/founder-saami.html" rel="noopener">
                https://www.elisence.com/founder-saami.html
              </a>
            </li>
            <li>
              Founder library & professional timeline:
              <a href="https://www.elisence.com/saami/" rel="noopener">
                https://www.elisence.com/saami/
              </a>
            </li>
            <li>
              Articles & ministry-grade evidence:
              <a href="https://www.elisence.com/articles.html" rel="noopener">
                https://www.elisence.com/articles.html
              </a>
            </li>
          </ul>
        </div>

        <div class="panel">
          <h2>What Elisence focuses on</h2>
          <p>
            Elisence covers multiple health domains under a single, non-diagnostic, privacy-first umbrella:
          </p>
          <ul class="link-list">
            <li>GLP-1 & metabolic health (Phase 1–3)</li>
            <li>Women+ health & family journeys (Phase 7)</li>
            <li>Mental health & dopamine balance (Phase 5 & 17)</li>
            <li>Nutrition, air quality and long-term risk (Phase 12 & 16)</li>
          </ul>
          <p>
            The UK microsite simply provides a clear, calm entry point for anyone in the United Kingdom who wishes to
            understand who Saami / Sami Salami Asl is and what Elisence actually does.
          </p>
          <small>
            This page does not provide medical advice, diagnosis or prescriptions. It only points to official Elisence
            documentation and public, non-diagnostic information.
          </small>
        </div>
      </section>

      <!-- NEW SECTION: all 11 UK evidence pages in matching blue cards -->
      <section class="articles-section">
        <h2 class="articles-title">UK evidence & articles for Saami / Sami Salami Asl</h2>
        <p class="articles-sub">
          The following pages sit under this UK microsite and give regulators, courts and investigators a stable,
          official narrative around the founder and the Elisence platform.
        </p>

        <div class="articles-grid">
          <!-- Founder overview (UK angle) -->
          <article class="article-card">
            <div class="article-eyebrow">Founder • UK context</div>
            <h3 class="article-title">About Saami Salami – UK overview</h3>
            <p class="article-text">
              Calm, structured biography of Saami / Sami Salami Asl, written for UK readers who need a neutral,
              professional reference.
            </p>
            <a class="article-link" href="about-saami-salami.html">Open about-saami-salami.html →</a>
          </article>

          <!-- Saami spelling -->
          <article class="article-card">
            <div class="article-eyebrow">Name mapping</div>
            <h3 class="article-title">“Saami Salami” – founder reference</h3>
            <p class="article-text">
              Explains how “Saami Salami” appears in documents and links this spelling back to the single founder
              identity behind Elisence.
            </p>
            <a class="article-link" href="saami-salami.html">Open saami-salami.html →</a>
          </article>

          <!-- Sami spelling -->
          <article class="article-card">
            <div class="article-eyebrow">Name mapping</div>
            <h3 class="article-title">“Sami Salami” – founder reference</h3>
            <p class="article-text">
              Clarifies that “Sami Salami” is the same person as Saami Salami Asl, preventing search or legal confusion.
            </p>
            <a class="article-link" href="sami-salami.html">Open sami-salami.html →</a>
          </article>

          <!-- Full surname -->
          <article class="article-card">
            <div class="article-eyebrow">Name mapping</div>
            <h3 class="article-title">“Saami / Sami Salami Asl” – full surname</h3>
            <p class="article-text">
              Shows how “Asl” appears in formal contexts, and ties all spellings back to one legal and professional identity.
            </p>
            <a class="article-link" href="sami-salami-asl.html">Open sami-salami-asl.html →</a>
          </article>

          <!-- UK specific -->
          <article class="article-card">
            <div class="article-eyebrow">Jurisdiction</div>
            <h3 class="article-title">Sami Salami – UK professional profile</h3>
            <p class="article-text">
              UK-centred profile for courts, regulators and employers who need a focused view on work done in the UK.
            </p>
            <a class="article-link" href="sami-salami-uk.html">Open sami-salami-uk.html →</a>
          </article>

          <!-- BBVP -->
          <article class="article-card">
            <div class="article-eyebrow">Methodology</div>
            <h3 class="article-title">BBVP methodology – build, verify, prove</h3>
            <p class="article-text">
              High-level explanation of the BBVP safety methodology used across Elisence: no feature is “done” without tests,
              evidence and traceability.
            </p>
            <a class="article-link" href="bbvp-methodology.html">Open bbvp-methodology.html →</a>
          </article>

          <!-- NHS -->
          <article class="article-card">
            <div class="article-eyebrow">Regulation</div>
            <h3 class="article-title">NHS digital safety alignment</h3>
            <p class="article-text">
              Shows how Elisence aligns to NHS-style clinical safety expectations without acting as a medical device.
            </p>
            <a class="article-link" href="nhs-digital-safety.html">Open nhs-digital-safety.html →</a>
          </article>

          <!-- EU MDR (note: filename uses “dighital” in repo) -->
          <article class="article-card">
            <div class="article-eyebrow">Regulation</div>
            <h3 class="article-title">EU MDR – digital health posture</h3>
            <p class="article-text">
              Positions Elisence next to EU MDR and CDS guidance: educational, decision-support style, not diagnostic or prescriptive.
            </p>
            <a class="article-link" href="eu-mdr-dighital-health.html">Open eu-mdr-dighital-health.html →</a>
          </article>

          <!-- FDA -->
          <article class="article-card">
            <div class="article-eyebrow">Regulation</div>
            <h3 class="article-title">FDA-compatible digital health stance</h3>
            <p class="article-text">
              Explains how Elisence can operate safely around US FDA expectations as a non-SaMD, non-prescriptive intelligence layer.
            </p>
            <a class="article-link" href="fda-digital-health.html">Open fda-digital-health.html →</a>
          </article>

          <!-- GCC -->
          <article class="article-card">
            <div class="article-eyebrow">Region</div>
            <h3 class="article-title">GCC digital health & PDPL alignment</h3>
            <p class="article-text">
              Describes Elisence’s fit with GCC ministries, PDPL-style privacy rules and national digital health strategies.
            </p>
            <a class="article-link" href="gcc-digital-health.html">Open gcc-digital-health.html →</a>
          </article>

          <!-- Zero trust -->
          <article class="article-card">
            <div class="article-eyebrow">Security</div>
            <h3 class="article-title">Zero-trust & security posture</h3>
            <p class="article-text">
              Overview of zero-trust, K-anonymity and WORM-style evidence needed for ministries, hospitals and legal reviews.
            </p>
            <a class="article-link" href="zero-trust-security.html">Open zero-trust-security.html →</a>
          </article>
        </div>
      </section>
    </main>

    <footer>
      <div class="footer-inner">
        <div>
          Built by Saami — Powered by ChatGPT • Elisence UK Microsite
        </div>
        <div>
          <a href="https://www.elisence.com/" rel="noopener">elisence.com</a>
        </div>
      </div>
    </footer>
  </div>
</body>
</html>
